574 related articles for article (PubMed ID: 15255181)
1. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors.
Overall CM; Tam EM; Kappelhoff R; Connor A; Ewart T; Morrison CJ; Puente X; López-Otín C; Seth A
Biol Chem; 2004 Jun; 385(6):493-504. PubMed ID: 15255181
[TBL] [Abstract][Full Text] [Related]
2. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer.
Overall CM; Dean RA
Cancer Metastasis Rev; 2006 Mar; 25(1):69-75. PubMed ID: 16680573
[TBL] [Abstract][Full Text] [Related]
3. Membrane protease degradomics: proteomic identification and quantification of cell surface protease substrates.
Butler GS; Dean RA; Smith D; Overall CM
Methods Mol Biol; 2009; 528():159-76. PubMed ID: 19153692
[TBL] [Abstract][Full Text] [Related]
4. Protease proteomics: revealing protease in vivo functions using systems biology approaches.
Doucet A; Overall CM
Mol Aspects Med; 2008 Oct; 29(5):339-58. PubMed ID: 18571712
[TBL] [Abstract][Full Text] [Related]
5. Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ).
Butler GS; Dean RA; Morrison CJ; Overall CM
Methods Mol Biol; 2010; 622():451-70. PubMed ID: 20135298
[TBL] [Abstract][Full Text] [Related]
6. Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates.
Tam EM; Morrison CJ; Wu YI; Stack MS; Overall CM
Proc Natl Acad Sci U S A; 2004 May; 101(18):6917-22. PubMed ID: 15118097
[TBL] [Abstract][Full Text] [Related]
7. Proteomic discovery of protease substrates.
Schilling O; Overall CM
Curr Opin Chem Biol; 2007 Feb; 11(1):36-45. PubMed ID: 17194619
[TBL] [Abstract][Full Text] [Related]
8. Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts.
Rosenthal EL; McCrory A; Talbert M; Carroll W; Magnuson JS; Peters GE
Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):943-7. PubMed ID: 15313864
[TBL] [Abstract][Full Text] [Related]
9. Cell-based identification of natural substrates and cleavage sites for extracellular proteases by SILAC proteomics.
Gioia M; Foster LJ; Overall CM
Methods Mol Biol; 2009; 539():131-53. PubMed ID: 19377966
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation.
Muñoz-Nájar UM; Neurath KM; Vumbaca F; Claffey KP
Oncogene; 2006 Apr; 25(16):2379-92. PubMed ID: 16369494
[TBL] [Abstract][Full Text] [Related]
11. N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification.
Huesgen PF; Overall CM
Physiol Plant; 2012 May; 145(1):5-17. PubMed ID: 22023699
[TBL] [Abstract][Full Text] [Related]
12. "Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products.
Piccard H; Hu J; Fiten P; Proost P; Martens E; Van den Steen PE; Van Damme J; Opdenakker G
Electrophoresis; 2009 Jul; 30(13):2366-77. PubMed ID: 19621364
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase proteomics: substrates, targets, and therapy.
Morrison CJ; Butler GS; Rodríguez D; Overall CM
Curr Opin Cell Biol; 2009 Oct; 21(5):645-53. PubMed ID: 19616423
[TBL] [Abstract][Full Text] [Related]
14. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics.
Butler GS; Overall CM
Biochemistry; 2009 Nov; 48(46):10830-45. PubMed ID: 19817485
[TBL] [Abstract][Full Text] [Related]
15. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity.
Uría JA; López-Otín C
Cancer Res; 2000 Sep; 60(17):4745-51. PubMed ID: 10987280
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the degradome with the CLIP-CHIP microarray.
Kappelhoff R; Auf dem Keller U; Overall CM
Methods Mol Biol; 2010; 622():175-93. PubMed ID: 20135282
[TBL] [Abstract][Full Text] [Related]
17. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.
Fayard B; Bianchi F; Dey J; Moreno E; Djaffer S; Hynes NE; Monard D
Cancer Res; 2009 Jul; 69(14):5690-8. PubMed ID: 19584287
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
Pawlik TM; Hawke DH; Liu Y; Krishnamurthy S; Fritsche H; Hunt KK; Kuerer HM
BMC Cancer; 2006 Mar; 6():68. PubMed ID: 16542425
[TBL] [Abstract][Full Text] [Related]
19. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry.
Butler GS; Overall CM
Curr Pharm Des; 2007; 13(3):263-70. PubMed ID: 17313360
[TBL] [Abstract][Full Text] [Related]
20. PNA-encoded protease substrate microarrays.
Winssinger N; Damoiseaux R; Tully DC; Geierstanger BH; Burdick K; Harris JL
Chem Biol; 2004 Oct; 11(10):1351-60. PubMed ID: 15489162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
